Met Life Investment Management, LLC Adc Therapeutics Sa Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Met Life Investment Management, LLC holds 43,089 shares of ADCT stock, worth $85,747. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,089
Previous 18,810
129.07%
Holding current value
$85,747
Previous $59,000
128.81%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ADCT
# of Institutions
80Shares Held
55.1MCall Options Held
82.7KPut Options Held
31.5K-
Redmile Group, LLC San Francisco, CA15.7MShares$31.2 Million3.23% of portfolio
-
Prosight Management, LP Dallas, TX9.64MShares$19.2 Million8.15% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.53MShares$9.02 Million0.34% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$7.07 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.04MShares$6.05 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $155M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...